Overview

Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma

Status:
Completed

Trial end date:
2017-09-22

Target enrollment:

Participant gender:

Summary

This is a single-center, single-arm, open-label, prospective phase 2 trial to assess the efficacy of localized concurrent chemoradiation therapy (CCRT) and sorafenib sequential therapy in subjects with advanced HCC. Approximately 47 subjects will be enrolled and will receive CCRT and sorafenib sequentially until all-cause mortality.

Phase:

Phase 2

Details

Lead Sponsor:

Yonsei University

Treatments:

Niacinamide
Sorafenib